ARS Pharmaceuticals Inc.

NASDAQ: SPRY · Real-Time Price · USD
14.47
0.31 (2.19%)
At close: May 02, 2025, 3:59 PM
14.17
-2.11%
Pre-market: May 05, 2025, 04:00 AM EDT
2.19%
Bid 14.16
Market Cap 1.42B
Revenue (ttm) 89.15M
Net Income (ttm) 8M
EPS (ttm) 0.08
PE Ratio (ttm) 180.94
Forward PE -25.81
Analyst Buy
Ask 15.25
Volume 840,508
Avg. Volume (20D) 1,642,906
Open 14.59
Previous Close 14.16
Day's Range 14.44 - 15.05
52-Week Range 7.55 - 18.51
Beta 0.98

About SPRY

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California....

Industry Biotechnology
Sector Healthcare
IPO Date Dec 4, 2020
Employees 155
Stock Exchange NASDAQ
Ticker Symbol SPRY
Full Company Profile

Analyst Forecast

According to 4 analyst ratings, the average rating for SPRY stock is "Buy." The 12-month stock price forecast is $29, which is an increase of 100.35% from the latest price.

Stock Forecasts

Next Earnings Release

ARS Pharmaceuticals Inc. is scheduled to release its earnings on May 16, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+22.83%
ARS Pharmaceuticals shares are trading higher. The... Unlock content with Pro Subscription
5 months ago
-15.23%
ARS Pharmaceuticals shares are trading lower after the company reported better-than-expected Q3 sales results.